---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: LEGEND"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: LEGEND. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 64 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence/legend"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: LEGEND

<a id="heading-3.1.3"></a>

## 3.1.3 LEGEND

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.1-2"></a>

#### Primary and secondary objectives in the statistical analysis plan

> “The primary objective of this study is to assess the effect of lanifibranor alone compared to placebo and the effect of lanifibranor in combination with empagliflozin compared to placebo on Haemoglobin A1C (HbA1c) after a 24-week treatment period.”
> “and to assess the safety and tolerability of lanifibranor alone and in combination with empagliflozin during the 24-week treatment period and the 4-week follow-up period.”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

<a id="topic-3.1.3.1-3"></a>

#### Objectives in the protocol: confirming the NATIVE glycemic effect and testing the empagliflozin combination

> “Confirm as primary objective the lanifibranor effect versus placebo on glycemic control observed in the NATIVE Phase 2b study (NCT03008070)”
> “Confirm a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control (i.e., conservation of the effect when associated with an SGLT2 inhibitor, no deleterious effect, no negative interaction on glycemic control)”
> “This study will allow evaluation of the effect of lanifibranor in combination with an SGLT2 inhibitor on body weight, peripheral edema, and anemia as safety endpoints.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.1-4"></a>

#### Rationale in the protocol for combining lanifibranor with an SGLT2 inhibitor

> “In addition, the combination of lanifibranor with an SGLT2 inhibitor may improve tolerability of the PPAR agonist. While lanifibranor has an overall favorable safety profile, weight gain, peripheral edema and anemia have been observed in Phase 2 studies, mainly in female patients.”
> “SGLT2 inhibitors induce weight loss and have a diuretic effect. They have also been shown to increase hematopoiesis.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.1-5"></a>

#### Proof-of-concept purpose and plans for the combination stated in the annual report

> “The LEGEND trial was intended to demonstrate proof of concept and the potential additional benefits of the combination between lanifibranor and empagliflozin and the possibility to address the weight gain observed in some patients treated with lanifibranor alone.”
> “We do not expect to further study the combination of lanifibranor and empagliflozin but expect to include the safety data from the LEGEND trial in a potential submission for marketing approval.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-06-29”
> “Primary Completion (Actual) 2024-05-08”
> “Study Completion (Actual) 2024-06-04”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.2-2"></a>

#### Registered locations

> “This study has 42 locations”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.2-3"></a>

#### Planned sites in the protocol synopsis

> “Approximately 30 sites across Europe and the United States of America (USA)”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.2-4"></a>

#### Recruitment period, screening, and results posting in the ClinicalTrials.gov results

> “Recruitment of patients started in June 2022 and last patient was recruited in November 2023. A total of 213 patients were screened for the study.”
> “Results First Posted 2026-09-09”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.2-5"></a>

#### Interim analysis data cut-off and date in the statistical analysis plan

> “An interim analysis will be conducted once approximately half of the planned patients will be randomized, and have either completed the 24-week treatment period or prematurely discontinued from treatment earlier as of 31-Jan-2024.”
> “The interim analysis was conducted on March 2024”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Three-arm design with an open-label combination arm in the protocol

> “The study is designed as a multinational, multicenter, three-arm, randomized, double-blind for lanifibranor and placebo, open-label for the combination lanifibranor plus empagliflozin, placebo-controlled, 24-week treatment study followed by a 4-week post-treatment visit.”
> “A total of 63 patients are planned to be randomized 1:1:1 to receive:”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.3-2"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
| Primary purpose | “Treatment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “39” |

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.3-3"></a>

#### Stratified randomization and sex quotas in the protocol

> “Randomization will be stratified by 2 stratifying factors: HbA1c at Screening (< 7.5%, ≥ 7.5%) and by sex (Male, Female), because these factors are considered important prognostic covariates.”
> “Moreover, at least 40% males and at least 40% females will be randomized.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.3-4"></a>

#### Rationale in the protocol for blinding the lanifibranor and placebo arms only

> “For that reason, a double-blind design was chosen for the lanifibranor and matching placebo arm to allow the assessment of the effect of lanifibranor versus placebo on HbA1c (primary endpoint) and other endpoints for glycemic control, liver tests, inflammatory markers, lipid parameters and body composition.”
> “For this purpose, an open-label design is deemed to be sufficient, for this proof-of-concept study.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.3-5"></a>

#### Interim analysis and stopping of recruitment

> “An interim analysis will be conducted once approximately half of the planned patients will be randomized, and have either completed the 24-week treatment period or prematurely discontinued from treatment earlier, that will constitute the Interim Analysis Set (IAS).”
> “Recruitment will be paused once the first half of the planned patients are randomized.”
> “Addition of an interim analysis (IA)”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

> “The primary endpoint was met. Therefore, recruitment has been stopped / not been re-initiated.”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

> “Given that the primary endpoint of LEGEND was met, and statistically significant results were achieved on several key additional markers, the Company has decided to stop the recruitment as defined per protocol.”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="topic-3.1.3.3-6"></a>

#### Treatment and follow-up periods in the poster

> “24-week treatment + 4-week follow-up”
> “Double blind for L and P, open label for L+E,”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Key inclusion criteria in the ClinicalTrials.gov record

> “Male or female, aged ≥ 18 years at the time of signing informed consent”
> “Diagnosis of NASH, based on histology or cT1≥875ms assessed by LiverMultiScan or cT1≥825ms assessed by LiverMultiScan and hepatic fat content ≥ 10% assessed by MRI-PDFF at screening”
> “HbA1c at screening ≥ 7.0 and ≤ 10.0%, on diet alone, or on metformin and/or dipeptidyl peptidase 4 inhibitor (DPP-IVi) therapy. Both with doses to be stable for 3 months”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.4-2"></a>

#### Key exclusion criteria in the ClinicalTrials.gov record: cirrhosis, prior therapies, and BMI

> “Histologically documented liver cirrhosis (fibrosis stage F4)”
> “Patient currently receiving any approved treatment for NASH or obesity”
> “Current treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA), insulin or sulfonylurea or treatment within the last 3 months prior to Screening”
> “Patients on pioglitazone in the last 12 months prior to Screening.”
> “BMI>45 kg/m2 at screening”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.4-3"></a>

#### Diagnosis of MASH by historical histology or noninvasive methods

> “The diagnosis of non-cirrhotic MASH/NASH was based on historic histology evaluation or a combination of non-invasive methods including diagnostic methods including imaging.”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="topic-3.1.3.4-4"></a>

#### Imaging definitions of NASH and the glycemic criterion in the protocol

> “NASH defined as cT1 ≥ 825 ms assessed by LiverMultiScan® and hepatic fat content ≥ 10% assessed by MRI-PDFF”
> “HbA1c at screening ≥ 7.0 and ≤ 10.0%, on diet alone, or on metformin (≥ 1,000 mg/day), and/or dipeptidyl peptidase 4 inhibitor (DPP-IVi) therapy.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.4-5"></a>

#### Cirrhosis exclusion by biopsy or noninvasive criteria in the protocol

> “Histologically documented liver cirrhosis (fibrosis stage F4), based on a historical biopsy (within 12 months prior to Screening); or diagnosis of cirrhosis at Screening based on clinic biochemical and imaging criteria (FibroScan® value confirmed ≥ 14 kPa and FIB-4 > 3.25 provided to the site by the central lab)”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.4-6"></a>

#### Other exclusion criteria in the protocol: weight change, NT-proBNP, renal function, and CYP2C8 interacting drugs

> “Weight change > 5% in the 3 months prior to Screening”
> “NT-proBNP > 900 pg/mL”
> “Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value < 60 mL/min as determined by Modification of Diet in Renal Disease [MDRD]”
> “Treatment with strong inducers or inhibitors of CYP2C8. When administered chronically, they should be replaced 3 months before Screening visit.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.4-7"></a>

#### Autoimmune liver and thyroid disease exclusion following NATiV3 Data Monitoring Committee recommendations

> “Any patient with a predisposition to autoimmune liver disease, including:”
> “Addition of the exclusion criteria n°50 related to autoimmunity and addition of corresponding laboratory parameters”
> “To mimic the recommendations issued by the Data Monitoring Committee for the Phase 3 study, NATiV3”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.4-8"></a>

#### Key inclusion criteria in the poster

> “historical biopsy with NAS ≥4”
> “Screening HbA1c in 7-10%”
> “MASH was diagnosed per historical liver biopsy or MRI imaging (cT1 or cT1+PDFF).”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Treatment arms in the ClinicalTrials.gov record

> “Lanifibranor (800 mg/day): two film-coated tablets of 400 mg each, once-a-day (QD) with food. For oral use. QD for 24 weeks.”
> “Two lanifibranor placebo-matching tablets once-a-day (QD) with food. For oral use. QD for 24 weeks.”
> “Lanifibranor (800 mg/day): two film-coated tablets of 400 mg each plus one empagliflozin film-coated tablet of 10 mg (10mg/day), once-a-day (QD) with food. For oral use. QD for 24 weeks”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.5-2"></a>

#### Investigational treatments, dose adjustment, and interruption rules in the protocol

> “Tablets of lanifibranor 400 mg, administered on a daily dose of 800 mg lanifibranor or placebo, i.e., 2 tablets of 400 mg/placebo orally once daily (QD) during breakfast, for a total of 24 weeks”
> “Tablets of empagliflozin 10 mg/day administered orally once daily during breakfast, for a total of 24 weeks”
> “No lanifibranor or empagliflozin dose adjustment is allowed in the study.”
> “Interruption of the IMP(s) due to AEs is allowed as per the Investigator’s discretion and medical judgment for a maximum of 15 days, and should occur only once during the 24-week treatment period”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.5-3"></a>

#### Background antidiabetic therapy, prohibited medications, and rescue medication in the protocol

> “These medicines will be continued at stable doses during the entire study.”
> “CYP2C8 strong inducers (e.g. rifampin). However, if medically necessary, these drugs may be taken for a maximum duration of 3 weeks.”
> “Rescue medication is defined as use of any new or additional antidiabetic medication, or increase in the dose of background antidiabetic medication above the baseline dose.”
> “Sulfonylureas, metformin, DPP-IVi may all be given as rescue medication until the end of the trial.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Change in HbA1c as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Primary endpoint as registered

> “Absolute Change in HbA1c”
> “Effect of lanifibranor alone compared to placebo and the effect of lanifibranor in combination with empagliflozin compared to placebo on absolute change in HbA1c from baseline (Week 0) to Week 24”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.6.1-2"></a>

##### Primary endpoint in the protocol and the poster

> “Absolute change in HbA1c from baseline (Week 0) to Week 24”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

> “Change in HbA1c from baseline to treatment week (TW) 24 was the primary efficacy endpoint.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="topic-3.1.3.6.1-3"></a>

##### Rationale: confirming the HbA1c decrease seen in NATIVE participants with type 2 diabetes

> “In this study in NASH patients, a sub-analysis on those patients with T2DM at baseline (i.e., with baseline HbA1c > 6.5%), demonstrated significant improvements in glycemic control, with a substantial decrease in HbA1c under treatment with lanifibranor. The present LEGEND study is intended to confirm these preliminary findings.”
> “mean absolute changes from baseline at Week 24: -0.60% [SD: 0.54%] and -0.72% [SD: 0.65%] in the lanifibranor 800 mg and 1200 mg groups versus 0.10% [SD: 0.53%] in the placebo group”
> “As described in Section 2.1 the major purpose of this study is to confirm as primary objective the lanifibranor effect versus placebo on glycemic control observed in the NATIVE Phase 2b study.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.6.1-4"></a>

##### Rationale: shared metabolic pathways of NASH and type 2 diabetes

> “Therapeutic compounds that address the upstream metabolic and immune mediated pathways of NASH are also expected to be beneficial for T2DM.”
> “The strong association of NASH and T2DM, both being manifestations of the metabolic syndrome, provides a compelling rationale for investigating therapies that work on multiple mechanisms and combining treatments with synergistic effects.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.6.1-5"></a>

##### Primary estimand in the statistical analysis plan

> “The primary estimand is the comparison of lanifibranor alone and lanifibranor plus empagliflozin versus placebo on the change in HbA1c from baseline to end of treatment (Week 24), on the population initiating treatment with lanifibranor or lanifibranor plus empagliflozin, and excluding potential rescue medication and potential significant diet changes affecting metabolism (under the hypothetical strategy where patients would have continued their treatment during 24 weeks without rescue medication or significant diet change).”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

<a id="topic-3.1.3.6.1-6"></a>

##### Secondary endpoints in the protocol: liver tests, glycemic response, body weight, and body composition

> “Change from baseline to Week 24 in liver tests (alanine aminotransferase [ALT], AST, gamma-glutamyl transferase (GGT), alkaline phosphatase [ALP], total and direct bilirubin)”
> “Binary endpoint defined as reaching HbA1c < 7.0% at Week 24, and no new antidiabetic treatment or increase in dosages of antidiabetic treatments”
> “Change from baseline to Week 24 in body weight”
> “Binary endpoint defined as reaching body weight increase ≥ 5% at Week 24”
> “Change from baseline to Week 24 in body composition as determined by MRI (including but not limited to: visceral adipose tissue [VAT], subcutaneous adipose tissue [SAT] and thigh SAT)”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.6.1-7"></a>

##### Adverse events of special interest in the protocol

> “Adverse Events of Special Interest (AESIs): anemia, heart failure, aminotransferase elevation, bone fracture, peripheral edema, cholelithiasis, hypoglycemia and ovulation resumption”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.6.1-8"></a>

##### Biomarker and MRI endpoints in the poster

> “Circulating biomarkers included liver enzymes, inflammation and fibrosis markers, lipid and glucose metabolism; MRI-based imaging included hepatic steatosis (PDFF), MASH composite disease activity and fibrosis (cT1), visceral (VAT) and subcutaneous (SAT) adipose tissue, spleen and liver volume; vital signs and safety were evaluated.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned sample size and power calculation in the protocol

> “Assuming an effect size of lanifibranor versus placebo of 0.60%, an expected SD of the change from baseline of 0.60%, a type I error of 0.05 (2-sided), an allocation ratio of 1:1, the required sample size per group is 21 patients with a power close to 90%.”
> “The total sample size is then 63 patients overall, distributed in 21 patients in each group.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.7.1-2"></a>

##### Treated participants in the full analysis set and participants in the primary MMRM analysis (registry)

> “39 patients were treated and included in the Full Analysis Set (FAS). Enrollment, disposition and analyses are based on the FAS (n=39).”
> “Two patients were not considered in the MMRM analysis because not having any post-treatment HbA1c values available:”
> “Overall Number of Participants Analyzed 11 13 13”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.7.1-3"></a>

##### Enrolled participants and completers in the poster

> “The LEGEND trial enrolled 39 patients (33 completers) with MASH and type-2 diabetes (T2D), randomized 1:1:1 to lanifibranor (L), lanifibranor with empagliflozin (L+E) and placebo (P)”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="topic-3.1.3.7.1-4"></a>

##### Participants in the interim analysis

> “Since the interim analysis (IA) will include only the 32 patients that have already completed their 24-week treatment period at time of 31st Jan 2024, there will be no need to pre-define an unblinded team at Inventiva to review the statistical results of these 32 study-completed patients.”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

> “As planned per protocol, the interim analysis was done once half of the 63 planned randomized patients with MASH completed the 24-week treatment period or prematurely discontinued from treatment.”
> “Two patients were not considered in the Full Analysis Set because we do not have post-treatment HbA1c values available”
> “Eight patients were not considered in the Completers set because of premature discontinuation before Week 24 or missing data due to prior intercurrent events (Rescue medication or significant diet modification affecting the primary endpoint).”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Analysis sets defined in the statistical analysis plan

> “The full analysis set (FAS) includes all randomized patients who received at least one dose of the assigned Investigational Medicinal Product (IMP), regardless of whether they prematurely discontinued randomized treatment or experienced any other intercurrent event, and meeting the targeted patient population of interest consistently with the primary estimand described in Section 12.5.2: Adults with non-cirrhotic NASH and T2DM defined by inclusion criteria No. 4 and 5 met, and exclusion criteria No. 2 and 15 not met.”
> “The Interim Analyis Set (IAS) consists of approximately the first half of the planned randomized patients from the FAS.”
> “The per protocol set (PPS) includes all patients in the FAS who do not have any major protocol deviations and who do not prematurely discontinue from treatment.”
> “The safety analysis set (SAS) includes all randomized patients who received at least one dose of IMP. Patients in the SAS will be analysed and summarized based on the treatment they actually received.”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

<a id="topic-3.1.3.7.2-2"></a>

##### Hierarchical testing, type I error, and multiplicity in the protocol

> “A hierarchical fixed testing procedure for the primary endpoint tests will be used; lanifibranor alone will be compared to placebo at the 2-sided 0.05 level on the primary endpoint, and, should this test pass, the combination will be tested at the same level.”
> “The overall type I error of the study is 0.05 (2-sided). No alpha (type I error) adjustment will be considered for the interim analysis, i.e. still considering 0.05 (2-sided), this study being an exploratory proof-of-concept study.”
> “No multiplicity adjustment when testing for treatment effect on secondary/exploratory endpoints will be done. P-values will be considered exploratory.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

> “No multiplicity adjustments when testing for treatment effect on secondary endpoints.”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.7.2-3"></a>

##### Mixed model for repeated measures for the primary endpoint in the registry

> “To assess the superiority of each active arm versus placebo on absolute change in HbA1c from baseline, a mixed model for repeated measures (MMRM) was used with treatment group, time, treatment×time interaction as fixed effects, baseline HbA1c value and sex as covariates and the patient effect as a random effect.”
> “The MMRM was used to handle missingness because outcomes are measured repeatedly over time. No explicit imputation was done for missing data”

Source: [ClinicalTrials.gov NCT05232071 API record](https://clinicaltrials.gov/api/v2/studies/NCT05232071)

<a id="topic-3.1.3.7.2-4"></a>

##### Handling of intercurrent events in the poster

> “Parameters sensitive to pre-defined intercurrent events (initiation of significant diet change affecting metabolism [1 patient in L+E after TW12] and initiation of a rescue medication [1 patient before TW4 in L and 1 patient after TW12 in P]) were analyzed excluding data after the occurrence of the intercurrent event.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Participant flow by arm in the ClinicalTrials.gov results

> “Arm/Group Title Lanifibranor (800 mg/Day) Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) Placebo”
> “Started 12 13 14”
> “Completed 12 12 9”
> “Not Completed 0 1 5”
> “Adverse Event 0 1 0”
> “Lost to Follow-up 0 0 2”
> “Non compliance with study drug 0 0 1”
> “Withdrawal by Subject 0 0 2”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.1-2"></a>

##### Screening and reasons for non-randomization in the ClinicalTrials.gov results

> “A total of 213 patients were screened for the study.”
> “Patients were invited to participate by their referent doctor based on their medical records. They had to fulfil all eligibility criteria. Main reason for non-randomization was screen failure.”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.1-3"></a>

##### Disposition by arm in the poster

> “Full analysis set 39 randomized and treated patients, 33 completed the 24-week treatment”
> “14 randomized and treated patients, 9 completed the 24-week treatment, 5 prematurely discontinued (2 withdrawal by patient, 2 lost to follow-up, 1 non-compliance with study drug)”
> “12 randomized and treated patients, 12 completed the 24-week treatment”
> “13 randomized and treated patients, 11 completed the 24-week treatment, 1 prematurely discontinued (AE)”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Demographics, glycemic stratum, and body size in the ClinicalTrials.gov baseline table

| Characteristic | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo | Total |
| --- | --- | --- | --- | --- |
| Participants | “12 participants” | “13 participants” | “14 participants” | “39 participants” |
| Age, years, mean (SD) | “55.1(11.45)” | “54.2(13.48)” | “54.7(13.01)” | “54.6(12.38)” |
| Female, n | “6” | “8” | “7” | “21” |
| White, n | “10” | “10” | “9” | “29” |
| Hispanic or Latino, n | “7” | “4” | “7” | “18” |
| HbA1c ≥7.5%, n | “8” | “8” | “9” | “25” |
| Weight, kg, mean (SD) | “93.30(11.614)” | “103.30(12.437)” | “94.50(21.269)” | “97.06(16.213)” |
| BMI, kg/m2, mean (SD) | “33.34(2.282)” | “37.62(4.300)” | “34.54(5.442)” | “35.19(4.554)” |

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.2-2"></a>

##### Median baseline characteristics in the poster

| Characteristic | Lanifibranor | Lanifibranor plus empagliflozin | Placebo | Total |
| --- | --- | --- | --- | --- |
| Age (years) | “55.5” | “54.0” | “55.5” | “55.0” |
| Sex (% female) | “6 (50)” | “8 (62)” | “7 (50)” | “21 (54)” |
| Country (% USA) | “11 (92)” | “12 (92)” | “12 (86)” | “35 (90)” |
| Weight (kg) | “93.9” | “99.9” | “97.4” | “97.2” |
| HbA1c (%) | “7.7” | “8.0” | “7.50” | “7.7” |
| ALT (U/L) | “53.0” | “52.0” | “33.0” | “39.0” |
| HOMA-IR | “9.4” | “10.9” | “16.3” | “10.8” |
| cT1 (ms) | “938” | “926” | “942” | “931” |
| MRI-PDFF (%) | “18.6” | “21.1” | “20.3” | “19.3” |

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Primary endpoint: absolute change in HbA1c from baseline to week 24, MMRM analysis (registry)

> “Two patients were not considered in the MMRM analysis because not having any post-treatment HbA1c values available:”
> “Least Squares Mean (95% Confidence Interval) | Unit of Measure: percentage of glycosylated hemoglobin”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

| Measure | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
| --- | --- | --- | --- |
| Participants analyzed | “11” | “13” | “13” |
| LS mean (95% CI) | “-1.11 (-1.6 to -0.62)” | “-1.54 (-2.02 to -1.06)” | “0.16 (-0.32 to 0.63)” |

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

| Comparison with placebo | LS mean difference | 95% CI lower limit | 95% CI upper limit | Standard error | p value |
| --- | --- | --- | --- | --- | --- |
| Lanifibranor 800 mg | “-1.27” | “-1.95” | “-0.58” | “0.33” | “< 0.001” |
| Lanifibranor 800 mg plus empagliflozin 10 mg | “-1.7” | “-2.38” | “-1.02” | “0.33” | “< 0.001” |

Source: [ClinicalTrials.gov NCT05232071 API record](https://clinicaltrials.gov/api/v2/studies/NCT05232071)

<a id="topic-3.1.3.8.3-2"></a>

##### Primary endpoint and HbA1c responders, FAS (poster)

> “Both L and L+E met the primary endpoint of HbA1c improvement versus P at TW24 (both p<0.001, FAS); 50% in both active arms reached HbA1c < 6.5% at TW24, with 58% and 80% HbA1c decrease ≥1% for L and L+E versus 0% for P, respectively.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="topic-3.1.3.8.3-3"></a>

##### HbA1c reduction and responders (company release, November 2024)

> “The study met the primary efficacy endpoint of HbA1c improvement with both treatment groups and patients treated with lanifibranor-only and in combination with empagliflozin showed a significant reduction in their HbA1c levels, with 50% of patients reaching an HbA1c under 6.5% by week 24 (p<0.001).”
> “Additionally, 58% of patients on lanifibranor alone and 80% of those on the combination therapy had a decrease of at least 1% in HbA1c at week 24, compared to 0% in the placebo group.”
> “November 15, 2024”

Source: [Inventiva LEGEND AASLD late-breaker release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-AASLD-Late-Breaker-EN-11-15-2024.pdf)

<a id="topic-3.1.3.8.3-4"></a>

##### Primary endpoint and HbA1c responders at the interim analysis, FAS and completers (company release, March 2024)

> “today announces positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND”
> “The study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c (HbA1c) of 1.14% and 1.59% in patients with MASH and T2D treated with lanifibranor (800mg daily) or in combination with empagliflozin (10mg daily) at week 24 compared to an increase of 0.26% observed in the placebo arm.”
> “Two patients were not considered in the Full Analysis Set because we do not have post-treatment HbA1c values available”
> “Eight patients were not considered in the Completers set because of premature discontinuation before Week 24 or missing data due to prior intercurrent events (Rescue medication or significant diet modification affecting the primary endpoint).”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

| Interim analysis measure | Placebo | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg |
| --- | --- | --- | --- |
| HbA1c, LS mean absolute change from baseline to week 24 (%), FAS | “0.26” | “-1.14” | “-1.59” |
| Participants, FAS | “(n=9)” | “(n=11)” | “(n=10)” |
| HbA1c <6.5% at week 24 (%), completers | “0” | “55” | “63” |
| HbA1c absolute decrease ≥1% at week 24 (%), completers | “0” | “64” | “88” |

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="topic-3.1.3.8.3-5"></a>

##### Hepatic steatosis by MRI-PDFF and cT1, LS mean change at week 24, FAS (poster)

> “Significant improvements of hepatic steatosis and composite MASH activity + fibrosis were observed for both L and L+E with mean relative MRI-PDFF changes of -49% (p=0.005) and -41% (p=0.02) and mean absolute cT1 changes of -86 and -75 ms respectively.”
> “LS mean relative change (%) from baseline to W24 in MRI-PDFF - FAS”
> “LS mean absolute change (ms) from baseline to W24 in cT1 - FAS”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="topic-3.1.3.8.3-6"></a>

##### Hepatic steatosis by MRI-PDFF at the interim analysis (company release, March 2024)

> “today announces positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND”
> “-47% and -38% respectively, compared to placebo (0%). 83% and 67% of patients treated with lanifibranor alone or in combination with empagliflozin respectively, showed a reduction greater or equal to 30% of their hepatic fat, compared to 0% in the placebo arm.”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="topic-3.1.3.8.3-7"></a>

##### Secondary endpoints at week 24, LS mean (95% CI), MMRM or ANCOVA (registry)

> “One patient under placebo was not considered in the MMRM analysis because no post-treatment values available (Premature discontinuation before Week 4)”
> “Sixteen patients were not considered in the ANCOVA analysis because of no VAT/SAT values available at Week 24:”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

| Outcome (unit) | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
| --- | --- | --- | --- |
| ALT, absolute change (U/L) | “-26.60 (-38.08 to -15.12)” | “-29.63 (-42.13 to -17.13)” | “-5.65 (-17.89 to 6.59)” |
| AST, absolute change (U/L) | “-13.67 (-20.66 to -6.68)” | “-17.81 (-25.5 to -10.12)” | “1.3 (-6.11 to 8.71)” |
| HOMA-IR, percentage change | “-50.79 (-95.69 to -5.89)” | “-45.23 (-89.86 to -0.61)” | “35.01 (-10.29 to 80.32)” |
| Insulin, percentage change | “-33.48 (-68.24 to 1.28)” | “-38.16 (-72.16 to -4.16)” | “10.17 (-23.63 to 43.96)” |
| Adiponectin, fold change | “2.87 (2.05 to 3.68)” | “3.03 (2.18 to 3.89)” | “1.24 (0.39 to 2.09)” |
| HDL cholesterol, relative change (%) | “16.48 (5.24 to 27.72)” | “15.30 (3.04 to 27.56)” | “2.55 (-9.76 to 14.86)” |
| VAT/SAT ratio, relative change (%) | “-4.6 (-14.44 to 5.25)” | “-17.45 (-28.67 to -6.23)” | “2.01 (-9.12 to 13.14)” |

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.3-8"></a>

##### Additional liver, fibrosis, inflammatory, and metabolic biomarkers, LS means at week 24 with p values (poster)

> “Liver tests (ALT, AST, GGT), fibrosis markers (TIMP-1, P3NP, Pro-C3), insulin, HOMA-IR, hs-CRP, ferritin, glycemia, lipid profile (HDL-C, Triglycerides) improved with L and L+E treatment, and adiponectin increased by a mean of 3-fold in both L and L+E arms compared to no increase for P.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

| LS mean at week 24 (p value versus placebo) | Lanifibranor | Lanifibranor plus empagliflozin | Placebo |
| --- | --- | --- | --- |
| GGT absolute change (IU/L) | “-21.9 (0.010)” | “-17.8 (0.015)” | “22.8” |
| TIMP-1 absolute change (ng/mL) | “-42.8 (0.040)” | “-40.0 (0.056)” | “-6.8” |
| Pro-C3 absolute change (ng/mL) | “-1.26 (0.120)” | “-3.54 (0.062)” | “7.33” |
| hs-CRP relative change (%) | “-32 (0.024)” | “-48 (0.008)” | “34” |
| Ferritin absolute change (µg/L) | “-78 (0.002)” | “-59 (0.022)” | “-8” |
| Glucose absolute change (mmol/L) | “-2.36 (0.005)” | “-1.98 (0.022)” | “-0.23” |
| Triglycerides relative change (%) | “-26 (0.006)” | “-27 (0.005)” | “-2” |

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="topic-3.1.3.8.3-9"></a>

##### Visceral to subcutaneous adipose tissue ratio and spleen volume, final analysis (poster) and interim analysis (company release)

> “The ratio VAT/SAT shifted favorably toward SAT for both L and L+E compared to placebo at TW24 (-5% and -17% vs +2%, respectively).”
> “Spleen volume decreased with L and L+E compared to placebo at TW24.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

> “today announces positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND”
> “Furthermore, these results demonstrated a significant relative reduction in the VAT/SAT ratio (visceral and subcutaneous adipose tissue) in patients treated with lanifibranor alone or in combination with empagliflozin, -5% and -17% respectively, compared to an increase of 11% in patients under placebo.”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="topic-3.1.3.8.3-10"></a>

##### Comparable effects of lanifibranor alone and with empagliflozin

> “The combination of lanifibranor with an SGLT2 inhibitor has comparable beneficial effects to lanifibranor alone on noninvasive hepatic and cardiometabolic markers of MASH, including a shift toward SAT, without observed weight gain.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

> “The improvement in cardiometabolic and hepatic markers of MASH was similar in both active treatment groups.”

Source: [Inventiva EASL SLD 2025 abstract release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-EASL-SLD-Abstract-01-22-2025.pdf)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Body weight, relative change from baseline to week 24, LS mean (95% CI) (registry)

> “Change in Body Weight and Body Composition (Body Weight)”
> “One patient under placebo was not considered in the MMRM analysis because of no post-treatment weight values available (premature discontinuation before Week 4)”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

| Measure | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
| --- | --- | --- | --- |
| Body weight, relative change (%) | “3.6 (2 to 5.19)” | “0.25 (-1.50 to 2.01)” | “-1.16 (-2.84 to 0.53)” |

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.5-2"></a>

##### Body weight with lanifibranor alone and with empagliflozin (poster and company release)

> “Patients had a mean weight increase of 3.6% with L at TW24, while mean weight remained unchanged in the L+E and placebo arms.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

> “Regarding weight, the lanifibranor-only group saw a small increase of 3.6%, while the weight remained stable in the group on lanifibranor and empagliflozin.”

Source: [Inventiva LEGEND AASLD late-breaker release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-AASLD-Late-Breaker-EN-11-15-2024.pdf)

<a id="topic-3.1.3.8.5-3"></a>

##### Mortality, serious adverse events, and selected other adverse events by arm (registry)

> “On or after the first dose of treatment up to 30 days post last dose.”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

| Event, affected / at risk (%) | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
| --- | --- | --- | --- |
| All-cause mortality | “0/12 (0.00%)” | “0/13 (0.00%)” | “0/14 (0.00%)” |
| Other (not including serious) adverse events, total | “10/12 (83.33%)” | “9/13 (69.23%)” | “8/14 (57.14%)” |
| Serious adverse event: haematuria | “0/12 (0.00%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Anemia | “2/12 (16.67%)” | “0/13 (0.00%)” | “1/14 (7.14%)” |
| Oedema peripheral | “0/12 (0.00%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Headache | “2/12 (16.67%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Nausea | “1/12 (8.33%)” | “2/13 (15.38%)” | “0/14 (0.00%)” |
| Alopecia | “2/12 (16.67%)” | “0/13 (0.00%)” | “0/14 (0.00%)” |
| Diabetes mellitus inadequate control | “0/12 (0.00%)” | “2/13 (15.38%)” | “0/14 (0.00%)” |
| Blood glucose decreased | “0/12 (0.00%)” | “1/13 (7.69%)” | “1/14 (7.14%)” |

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.5-4"></a>

##### Tolerability statements by the company

> “L and L+E were safe and well tolerated.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

> “The treatment with lanifibranor 800mg/daily alone and in combination with empagliflozin 10mg/daily for 24 weeks appears to be well tolerated, with no safety concerns reported.”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary: sample size, early stop of recruitment, open-label arm, and multiplicity

- The protocol planned 63 participants (21 per group) for power close to 90%, assuming an HbA1c effect of 0.60% versus placebo. The protocol paused recruitment for an interim analysis once half of the planned participants were randomized; because the primary endpoint was met, recruitment was stopped. A total of 39 participants were treated (12 with lanifibranor, 13 with lanifibranor plus empagliflozin, and 14 with placebo) out of 213 screened.
- The lanifibranor and placebo arms were double-blind, and the lanifibranor plus empagliflozin arm was open-label.
- Treatment lasted 24 weeks, followed by a 4-week follow-up.
- No alpha adjustment was applied for the interim analysis, the protocol describing the trial as an “exploratory proof-of-concept study”, and no multiplicity adjustment was made for secondary endpoints.
- Inventiva does not expect to further study the combination of lanifibranor and empagliflozin.

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf); [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf); [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf); [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results); [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.3.9-2"></a>

#### Summary: population, endpoints, missing data, and figures that differ by source

- MASH was diagnosed by historical histology or noninvasive methods, including cT1 thresholds on LiverMultiScan with or without MRI-PDFF. Participants had type 2 diabetes with HbA1c of 7.0% to 10.0% on diet, metformin, and/or a DPP-4 inhibitor; current or recent treatment with GLP-1 receptor agonists, insulin, or sulfonylureas was excluded. In the poster, 35 of 39 participants (90%) were enrolled in the United States.
- The primary endpoint was the change in HbA1c; other endpoints were circulating biomarkers and MRI-based imaging.
- In the placebo arm, 9 of 14 participants completed treatment (2 withdrawals, 2 lost to follow-up, 1 noncompliance). Two participants without post-treatment HbA1c values were excluded from the MMRM analysis, which used no explicit imputation, and 16 participants without week 24 VAT/SAT values were excluded from that ANCOVA analysis. Data after an intercurrent event (rescue medication in 2 participants and a significant diet change in 1) were excluded.
- The interim analysis (FAS, n=11, 10, and 9) reported HbA1c changes of -1.14% and -1.59% with lanifibranor and the combination versus +0.26% with placebo; the final registry analysis reports -1.11, -1.54, and 0.16. The VAT/SAT ratio with placebo increased by 11% in the interim release and by 2% in the final poster. Completers in the combination arm are 11 in the poster and 12 in the registry participant flow.

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf); [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071); [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf); [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results); [ClinicalTrials.gov NCT05232071 API record](https://clinicaltrials.gov/api/v2/studies/NCT05232071)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
